VanEck Associates’s GoodRx Holdings GDRX Stock Holding History

VanEck Associates’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,173	Closed	-$5K	–	1436
2022 Q3	$5K	Buy	+1,173	New	+$7.39K	﹤0.01%	1347

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PTC

Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TCMX

Technology Crossover Management X Menlo Park, California $781M AUM 18.39% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VanEck Associates's GDRX Position: Q4 2022 in Review

VanEck Associates sold out of GoodRx Holdings (GDRX) in Q4 2022, closing a stake of 1,173 shares — an estimated $5K sold.

VanEck Associates first reported a position in GDRX in Q3 2022 and held it in 1 quarter. The position peaked at $5K in Q3 2022. 160 funds tracked by Wall St. Rank hold GDRX as of Q4 2022.

VanEck Associates reported no remaining GoodRx Holdings position as of Q4 2022 after selling out during the quarter.
VanEck Associates sold 1,173 GoodRx Holdings shares in Q4 2022, an estimated $5K.
VanEck Associates first reported a position in GoodRx Holdings in Q3 2022 and held it in 1 quarter.
VanEck Associates's GoodRx Holdings position peaked at $5K in Q3 2022.
160 funds tracked by Wall St. Rank held GoodRx Holdings as of Q4 2022.

Based on VanEck Associates's 13F filing for Q4 2022, filed 8 Feb 2023.